Bio-industry is one of the leading high-tech industries in 2 1 century, and it is an important driving force for global economic and social development in the future. Its high added value can fill the industrial vacancy after the transfer of general traditional industries, help to adjust and optimize the industrial structure, and promote sustainable economic development. At present, the pharmaceutical market share in the United States accounts for about 18% of GDP, which is nearly $4 trillion, while the pharmaceutical industry in China only accounts for about 2% of GDP every year. The development of biological resources development and innovation industry must be supported by big projects and good projects, which is the key to the development and innovation of production resources. Wu Hongjiang, the chairman of the company, saw this historical development opportunity, so he joined hands with the Institute of Microbiology of the Chinese Academy of Sciences to form a strategic partnership and jointly promote the project construction. As the bio-industry innovation base and bio-technology transformation base of Institute of Microbiology, China Academy of Sciences, "Zhongke Acer Pingyao Biotechnology Industrial Park" will establish technical service platforms such as joint laboratories and R&D centers with the company. Through the effective implementation of the project, it will be market-oriented, timely transform leading scientific research achievements at home and abroad, and develop the bio-industry in clusters.
The implementation of the project has high market space, high growth and considerable market share, and there is no intellectual property dispute. Therefore, it is very necessary and feasible to build "Zhongke Acer Pingyao Biotechnology Industrial Park".